Dimerix secures A$34 million non-dilutive loan facility
Dimerix has secured non-dilutive loan facility agreements to fund key clinical milestones, totaling A$34 million.
MELBOURNE, Australia, Sept.
4, 2026 // -- Dimerix Limited (ASX:DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has successfully secured non-dilutive loan facility agreements ("Loan Agreements") with a group of…